The article mentions that Akero Therapeutics has received 5 bullish analyst ratings in the last quarter, with an average price target of $61.4, which is higher than the current price of $53.24. This indicates a potential upside for the stock, making it likely to go up in the short term. The average price target has also increased by 4.96% from the previous average, further supporting the bullish sentiment.